Data published in The New England Journal of Medicine demonstrate RYBREVANT®▼(amivantamab) plus LAZCLUZE®▼ (lazertinib) could re-set survival expectations in first-line EGFR-mutated advanced lung cancer
Chemotherapy-free combination regimen has the potential to usher in new era for first-line treatment, with median overall survival projected to...